Halozyme Therapeutics (HALO) Shares Outstanding (2010 - 2026)

Halozyme Therapeutics (HALO) has reported Shares Outstanding (Entity) for 17 consecutive years, with $118.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) fell 3.77% year-over-year to $118.5 million; the TTM figure through Mar 2026 stood at $118.5 million (down 3.77% YoY), while the FY2025 annual figure was $117.8 million, down 4.35% from the prior year.
• Shares Outstanding (Entity) improved to $118.5 million in Q1 2026 per HALO's latest filing, from $117.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $137.9 million in Q1 2022 and bottomed at $117.5 million in Q3 2025.
• Historically, Shares Outstanding (Entity) has averaged $127.5 million across 5 years, with a median of $127.2 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) dropped 1.7% — and 2025, when it fell 7.6%.
• Halozyme Therapeutics' Shares Outstanding (Entity) stood at $135.2 million in 2022, then dropped by 6.2% to $126.8 million in 2023, then retreated by 2.87% to $123.1 million in 2024, then retreated by 4.35% to $117.8 million in 2025, then climbed by 0.63% to $118.5 million in 2026.
• Business Quant data shows HALO's Shares Outstanding (Entity) at $118.5 million in Q1 2026, $117.8 million in Q4 2025, and $117.5 million in Q3 2025.